MCID: ESN005
MIFTS: 53

Eosinophilic Gastroenteritis

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Eosinophilic Gastroenteritis

MalaCards integrated aliases for Eosinophilic Gastroenteritis:

Name: Eosinophilic Gastroenteritis 12 77 60 56 15 74
Eosinophilic Gastroenterocolitis 60
Gastroenteritis, Eosinophilic 77
Eosinophilic Enteropathy 74
Eosinophilic Enteritis 60
Ege 60

Characteristics:

Orphanet epidemiological data:

60
eosinophilic gastroenteritis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



Summaries for Eosinophilic Gastroenteritis

MalaCards based summary : Eosinophilic Gastroenteritis, also known as eosinophilic gastroenterocolitis, is related to gastroenteritis and hypereosinophilic syndrome, idiopathic. An important gene associated with Eosinophilic Gastroenteritis is CCL11 (C-C Motif Chemokine Ligand 11), and among its related pathways/superpathways are JAK-STAT signaling pathway (KEGG) and Allograft rejection. The drugs Fluticasone and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and bone, and related phenotypes are eosinophilia and dysphagia

Wikipedia : 77 Eosinophilic gastroenteritis (EG) is a rare and heterogeneous condition characterized by patchy or... more...

Related Diseases for Eosinophilic Gastroenteritis

Diseases related to Eosinophilic Gastroenteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 gastroenteritis 30.7 ALB CCL11 IL5 RNASE3 TSLP
2 hypereosinophilic syndrome, idiopathic 30.3 IL3 IL5
3 milk allergy 30.2 IL5 RNASE3
4 esophagitis, eosinophilic, 1 30.2 CCL11 IL5 TSLP
5 esophagitis 30.2 CCL11 IL5 TSLP
6 churg-strauss syndrome 30.0 IL5 RNASE3
7 dermatitis 30.0 CCL11 IL5 TSLP
8 allergic bronchopulmonary aspergillosis 29.7 EPX IL5
9 eosinophilic granuloma 29.7 EPX RNASE3
10 chronic eosinophilic pneumonia 29.5 CCL11 IL5 RNASE3
11 food allergy 29.5 ALB EPX IL5 RNASE3
12 hypereosinophilic syndrome 29.4 CCL11 EPX IL3 IL5 RNASE3
13 eosinophilic pneumonia 29.4 CCL11 IL3 IL5 RNASE3
14 bronchitis 29.2 ALB CCL11 IL5 RNASE3
15 asthma 28.7 CCL11 EPX IL3 IL5 RNASE3 TSLP
16 allergic asthma 28.5 CCL11 EPX IL5 RNASE3 TSLP
17 allergic hypersensitivity disease 28.1 CCL11 EPX IL3 IL5 RNASE3 TSLP
18 eosinophilic enteropathy 12.0
19 megalencephaly-capillary malformation-polymicrogyria syndrome 11.1
20 aplastic anemia 11.1
21 pyridoxine deficiency anemia 11.1
22 exercise-induced anaphylaxis 11.1
23 paroxysmal cold hemoglobinuria 11.1
24 protein-losing enteropathy 10.3
25 pancreatitis 10.3
26 colitis 10.2
27 pyloric stenosis 10.2
28 seborrheic infantile dermatitis 10.2 IL3 IL5
29 pemphigoid gestationis 10.2 CCL11 IL5
30 duodenal ulcer 10.2
31 acute pancreatitis 10.2
32 chronic meningitis 10.2 CCL11 IL5
33 angiostrongyliasis 10.2 CCL11 IL5
34 strongyloidiasis 10.2 CCL11 IL5
35 loeffler endocarditis 10.2 IL5 RNASE3
36 eosinophilic meningitis 10.2 CCL11 IL5
37 paragonimiasis 10.2 IL5 RNASE3
38 cough variant asthma 10.2 IL5 RNASE3
39 duodenal obstruction 10.2
40 cow milk allergy 10.2 IL5 RNASE3
41 folliculitis 10.2 CCL11 IL5
42 drug allergy 10.1 ALB IL5
43 radiculopathy 10.1 CCL11 IL5
44 latex allergy 10.1 IL5 RNASE3
45 status asthmaticus 10.1 IL5 RNASE3
46 blepharoconjunctivitis 10.1 CCL11 RNASE3
47 sinusitis 10.1 IL5 RNASE3
48 giant papillary conjunctivitis 10.1 CCL11 RNASE3
49 chloramine t respiratory allergy 10.1 ALB RNASE3
50 crohn's disease 10.1

Graphical network of the top 20 diseases related to Eosinophilic Gastroenteritis:



Diseases related to Eosinophilic Gastroenteritis

Symptoms & Phenotypes for Eosinophilic Gastroenteritis

Human phenotypes related to Eosinophilic Gastroenteritis:

60 33 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 eosinophilia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001880
2 dysphagia 60 33 frequent (33%) Frequent (79-30%) HP:0002015
3 vomiting 60 33 frequent (33%) Frequent (79-30%) HP:0002013
4 anemia 60 33 frequent (33%) Frequent (79-30%) HP:0001903
5 abdominal pain 60 33 frequent (33%) Frequent (79-30%) HP:0002027
6 elevated c-reactive protein level 60 33 frequent (33%) Frequent (79-30%) HP:0011227
7 hypoalbuminemia 60 33 frequent (33%) Frequent (79-30%) HP:0003073
8 steatorrhea 60 33 frequent (33%) Frequent (79-30%) HP:0002570
9 allergic rhinitis 60 33 frequent (33%) Frequent (79-30%) HP:0003193
10 ascites 60 33 occasional (7.5%) Occasional (29-5%) HP:0001541
11 edema 60 33 occasional (7.5%) Occasional (29-5%) HP:0000969
12 weight loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0001824
13 asthma 60 33 occasional (7.5%) Occasional (29-5%) HP:0002099
14 hematochezia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002573
15 elevated erythrocyte sedimentation rate 60 33 occasional (7.5%) Occasional (29-5%) HP:0003565
16 protein-losing enteropathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0002243
17 atopic dermatitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001047
18 malabsorption 60 Frequent (79-30%)
19 leukocytosis 60 Frequent (79-30%)
20 diarrhea 60 Frequent (79-30%)
21 abnormality of the gastrointestinal tract 60 Frequent (79-30%)
22 abnormal test result 60 Frequent (79-30%)

Drugs & Therapeutics for Eosinophilic Gastroenteritis

Drugs for Eosinophilic Gastroenteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
2
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 5281004 63006
3
Lansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
4
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 138530-94-6, 103577-45-3 9578005
5
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
6 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Cromolyn Sodium Phase 4
18 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Not Applicable
20 Soy Bean Phase 4,Phase 2,Phase 3,Not Applicable
21 Olive Phase 4
22 Antacids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
23 Anti-Ulcer Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
24 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
25 Proton Pump Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
26
Montelukast Approved Phase 3,Phase 1,Not Applicable 158966-92-8 5281040
27 Reslizumab Approved, Investigational Phase 3,Phase 2
28
Esomeprazole Approved, Investigational Phase 2, Phase 3,Not Applicable 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
29
Histamine Approved, Investigational Phase 3 51-45-6 774
30
Ketotifen Approved Phase 3 34580-14-8, 34580-13-7 3827
31 Leukotriene Antagonists Phase 3,Phase 1,Not Applicable
32 Antibodies Phase 3,Phase 2,Phase 1
33 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
34 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
35 Immunoglobulins Phase 3,Phase 2,Phase 1
36 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
37 Antipruritics Phase 3,Not Applicable
38 Histamine Antagonists Phase 3
39
Histamine Phosphate Phase 3 51-74-1 65513
40 Histamine H1 Antagonists Phase 3
41
Omalizumab Approved, Investigational Phase 2,Phase 1 242138-07-4
42
Infliximab Approved Phase 2 170277-31-3
43
Benzocaine Approved, Investigational Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
44
tannic acid Approved Phase 2,Not Applicable 1401-55-4
45 Benralizumab Approved, Investigational Phase 1, Phase 2 1044511-01-4
46
Losartan Approved Phase 2 114798-26-4 3961
47
Angiotensin II Approved, Investigational Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
48
Bethanechol Approved Phase 2 674-38-4 2370
49
mometasone furoate Approved, Investigational, Vet_approved Phase 2 83919-23-7
50 Caseins Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 140)
# Name Status NCT ID Phase Drugs
1 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
3 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
4 EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone Recruiting NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
5 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
6 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
7 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed NCT00635089 Phase 3 reslizumab
8 Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
9 A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Completed NCT02605837 Phase 3 Oral Budesonide Suspension (OBS);Placebo
10 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
11 Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Completed NCT02610816 Phase 2, Phase 3 Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
12 A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Completed NCT00266578 Phase 3 Fluticasone Propionate
13 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
14 Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03245840 Phase 3 Budesonide oral suspension
15 Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Recruiting NCT03633617 Phase 3 Dupilumab;Placebo
16 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Recruiting NCT02778867 Phase 2, Phase 3 Flovent
17 Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia Recruiting NCT02484248 Phase 3 Ketotifen;Placebo
18 Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Active, not recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
19 An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
20 Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis Completed NCT00762073 Phase 2 budesonide;placebo
21 A Study of Flovent in Patients With Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
22 Budesonide for Eosinophilic Esophagitis Completed NCT00271349 Phase 2 Budesonide
23 Milk Patch for Eosinophilic Esophagitis Completed NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
24 Topical Steroid Treatment for Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
25 Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
26 Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
27 Omalizumab to Treat Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
28 Proof of Concept Study of OC000459 in Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
29 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
30 Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
31 Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
32 Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE) Completed NCT02379052 Phase 2 Dupilumab;Placebo
33 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
34 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
35 OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
36 Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
37 Intravenous Mepolizumab In Children With Eosinophilic Esophagitis Completed NCT00358449 Phase 2 mepolizumab
38 An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients Completed NCT00274703 Phase 2 mepolizumab
39 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
40 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
41 A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Recruiting NCT03496571 Phase 2 AK002
42 Benralizumab for Eosinophilic Gastritis Recruiting NCT03473977 Phase 1, Phase 2
43 Mepo for EoE Study Recruiting NCT03656380 Phase 2 Mepolizumab 300 mg;Mepolizumab 100 mg
44 Eosinophilic Esophagitis Clinical Therapy Comparison Trial Active, not recruiting NCT01821898 Phase 2 Oral Budesonide
45 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT03191864 Phase 2 APT-1011;Placebo
46 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT03029091 Phase 2 Losartan Potassium
47 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Active, not recruiting NCT01808196 Phase 2 Losartan Potassium
48 An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Enrolling by invitation NCT03664960 Phase 2 AK002
49 DEGS - Dupilumab for Eosinophilic Gastritis Study Not yet recruiting NCT03678545 Phase 2 Dupilumab (blinded);Placebo (blinded);Dupilumab (open-label)
50 Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis Not yet recruiting NCT02873468 Phase 2 Florence 30 μg/mL;Florence 60 μg/mL;Florence 90 μg/mL

Search NIH Clinical Center for Eosinophilic Gastroenteritis

Genetic Tests for Eosinophilic Gastroenteritis

Anatomical Context for Eosinophilic Gastroenteritis

MalaCards organs/tissues related to Eosinophilic Gastroenteritis:

42
Colon, Testes, Bone, Small Intestine, Skin, Liver, T Cells

Publications for Eosinophilic Gastroenteritis

Articles related to Eosinophilic Gastroenteritis:

(show top 50) (show all 439)
# Title Authors Year
1
Eosinophilic Gastroenteritis Presenting With Gastric Perforation. ( 29366927 )
2019
2
Eosinophilic gastroenteritis: An unusual presentation of a rare disease. ( 29555104 )
2019
3
Clinical and pathological profile of eosinophilic gastroenteritis. ( 30113369 )
2019
4
Abdominal ascites in children as the presentation of eosinophilic gastroenteritis: A surgeon's perspective. ( 30528318 )
2019
5
A Case of Eosinophilic Gastroenteritis Associated with Eosinophilic Ascites Diagnosed by Full-Thickness Biopsy of the Small Intestine. ( 30755542 )
2019
6
Abnormal thymic stromal lymphopoietin expression in the gastrointestinal mucosa of patients with eosinophilic gastroenteritis. ( 30763528 )
2019
7
Modified oral enteric-coated budesonide regimens to treat pediatric eosinophilic gastroenteritis, a single center experience. ( 30763733 )
2019
8
Clinical features and treatment outcomes of eosinophilic gastroenteritis : an analysis of 28 cases. ( 30888747 )
2019
9
Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab. ( 30982212 )
2019
10
Endoscopic Features and Diagnostic Procedures of Eosinophilic Gastroenteritis. ( 30996166 )
2019
11
Efficacy of an elimination diet in a patient with eosinophilic gastroenteritis : a pediatric case with multiple food allergies. ( 31064942 )
2019
12
Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab. ( 30056148 )
2018
13
Eosinophilic gastroenteritis complicating acute calculus eosinophilic cholecystitis 6 months after cholecystectomy. ( 30370999 )
2018
14
Eosinophilic Gastroenteritis and Colitis: Not Yet Ready for the Big Leagues. ( 29620603 )
2018
15
Post-partum eosinophilic gastroenteritis: A case report. ( 28081983 )
2018
16
A Prospective Study on the Prevalence, Extent of Disease and Outcome of Eosinophilic Gastroenteritis in Patients Presenting with Lower Abdominal Symptoms. ( 29212311 )
2018
17
Eosinophilic Gastroenteritis in Which Obstructive Jaundice Developed due to Invagination of the Duodenal Wall. ( 29434146 )
2018
18
Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus. ( 29533199 )
2018
19
Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis. ( 29596982 )
2018
20
Successful Food-Elimination Diet in an Adult with Eosinophilic Gastroenteritis. ( 29850645 )
2018
21
Ascites in a Young Woman: A Rare Presentation of Eosinophilic Gastroenteritis. ( 29862093 )
2018
22
Takayasu's arteritis associated with eosinophilic gastroenteritis, possibly via the overactivation of Th17. ( 29942355 )
2018
23
Massive hemorrhagic ascites: A rare presentation of eosinophilic gastroenteritis. ( 30079343 )
2018
24
Prevalence of Eosinophilic Gastroenteritis and Colitis in a Population-Based Study, From 2012 to 2017. ( 28603057 )
2017
25
Eosinophilic gastroenteritis: A state-of-the-art review. ( 27253425 )
2017
26
Eosinophilic gastroenteritis in a teenager: A rare diagnosis. ( 27283450 )
2017
27
Eosinophilic gastroenteritis: three clinical cases with different presentations. ( 28063615 )
2017
28
Eosinophilic Gastroenteritis Presenting with Red Streaking. ( 28250308 )
2017
29
Eosinophilic gastroenteritis caused by eating hens' eggs: A case report. ( 28279648 )
2017
30
Hematemesis as Initial Presentation in a 10-Week-Old Infant with Eosinophilic Gastroenteritis. ( 28299223 )
2017
31
CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis. ( 28497923 )
2017
32
Diagnosis of eosinophilic gastroenteritis is easily missed. ( 28596692 )
2017
33
Lack of Knowledge and Low Readiness for Health Care Transition in Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 28644350 )
2017
34
Eosinophilic gastroenteritis presenting as upper gastrointestinal hematoma and ulcers after endoscopic biopsy: A case report and literature review. ( 28906408 )
2017
35
Serum Biomarkers for the Diagnosis of Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 28943560 )
2017
36
Eosinophilic Ascites: Uncommon Presentation of Eosinophilic Gastroenteritis in a Young Adult Male. ( 29255753 )
2017
37
Eosinophilic Ascites-Rarest Presentation of a Rare Disease, Eosinophilic Gastroenteritis. ( 29313586 )
2017
38
Eosinophilic gastroenteritis; a report of two cases with different presentations. ( 29511487 )
2017
39
Subserous Eosinophilic Gastroenteritis: A Rare Cause of Ascites. ( 30755942 )
2017
40
Severe Eosinophilic Gastroenteritis in a Crohn's Disease Patient Treated With Infliximab and Adalimumab. ( 27018120 )
2016
41
A Case of Eosinophilic Gastroenteritis Forming a Rigid Chamber Mimicking Giant Duodenal Ulcer on Computed Tomography Imaging. ( 27086704 )
2016
42
Eosinophilic Esophagitis, Eosinophilic Gastroenteritis, and Eosinophilic Colitis: Common Mechanisms and Differences between East and West. ( 29922659 )
2016
43
Eosinophilic Gastroenteritis and Colitis: a Comprehensive Review. ( 26054822 )
2016
44
Severe eosinophilic gastroenteritis. ( 26802190 )
2016
45
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency. ( 26840762 )
2016
46
Sera of patients with infantile eosinophilic gastroenteritis showed a specific increase in both thymic stromal lymphopoietin and IL-33 levels. ( 26948075 )
2016
47
Eosinophilic Gastroenteritis: An Underdiagnosed Condition. ( 27234270 )
2016
48
Eosinophilic Gastroenteritis as a Rare Cause of Recurrent Epigastric Pain. ( 27274524 )
2016
49
Eosinophilic Gastroenteritis : Brief Review. ( 27382945 )
2016
50
Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate. ( 27466473 )
2016

Variations for Eosinophilic Gastroenteritis

Expression for Eosinophilic Gastroenteritis

Search GEO for disease gene expression data for Eosinophilic Gastroenteritis.

Pathways for Eosinophilic Gastroenteritis

GO Terms for Eosinophilic Gastroenteritis

Cellular components related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 ALB CCL11 EPX IL3 IL5 RNASE3
2 extracellular space GO:0005615 9.17 ALB CCL11 EPX IL3 IL5 RNASE3

Biological processes related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.54 CCL11 IL3 IL5
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.32 IL3 IL5
3 cellular oxidant detoxification GO:0098869 9.26 ALB EPX
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.16 IL3 TSLP
5 cytokine-mediated signaling pathway GO:0019221 9.13 CCL11 IL3 IL5
6 regulation of signaling receptor activity GO:0010469 8.92 CCL11 IL3 IL5 TSLP

Molecular functions related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 CCL11 IL3 IL5 TSLP

Sources for Eosinophilic Gastroenteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....